Apothecon To Continue As Bristol Unit After Sale Of Generics To Novartis
Executive Summary
Bristol Myers-Squibb will continue to market generic drugs internationally and its branded generics in the U.S. following the sale of U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis.
You may also be interested in...
Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist
Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone
Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist
Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone
AHP Exiting Oral Generics Business; K-Dur Settlement With FTC Near
American Home Products is phasing out its oral solid dosage form generic drug business, the company said in documents filed as part of the Federal Trade Commission suit against ESI Lederle